---
title: "Notable healthcare headlines for the week: Novo Nordisk, Novartis and UnitedHealth in focus"
description: "Wall Street's major averages closed mixed, with the Nasdaq Composite reaching new highs. The S&P 500 Health Care Index gained 1.3%. Notable healthcare stories include Trump pressuring drug companies t"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/257252327.md"
published_at: "2025-09-14T13:16:43.000Z"
---

# Notable healthcare headlines for the week: Novo Nordisk, Novartis and UnitedHealth in focus

> Wall Street's major averages closed mixed, with the Nasdaq Composite reaching new highs. The S&P 500 Health Care Index gained 1.3%. Notable healthcare stories include Trump pressuring drug companies to lower prices, Novo Nordisk cutting 9,000 jobs, and UnitedHealth's Medicare Star Ratings update. Novartis announced a $1.4 billion acquisition of Tourmaline Bio, while AbbVie settled with generic drugmakers over Rinvoq. Top healthcare gainers included Centene and UnitedHealth, while Humana and Charles River Laboratories were among the losers.

Wall Street's major averages closed mixed on Friday, with the Nasdaq Composite (COMP:IND) closing at new highs every day of the week, while the Dow (DJI) retreated from the 46k level. The Nasdaq Composite (COMP:IND) set a fifth consecutive record closing of 22,141.10 points, ending +0.4%. The benchmark S&P 500 (SP500) broke its winning streak and c...

### Related Stocks

- [UNH.US - Unitedhealth](https://longbridge.com/en/quote/UNH.US.md)
- [CNC.US - Centene](https://longbridge.com/en/quote/CNC.US.md)
- [NVO.US - Novo Nordisk AS](https://longbridge.com/en/quote/NVO.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 諾和諾德公司 - 股份回購計劃 | 諾和諾德公司已啓動一項最高達 150 億丹麥克朗的股票回購計劃，計劃於 2026 年 2 月 4 日開始。截至 2026 年 2 月 13 日，公司已回購 1,750,000 股 B 類股票，平均價格為 305.03 丹麥克朗，總計為 53 | [Link](https://longbridge.com/en/news/276056741.md) |
| 諾和諾德公司獲得歐洲委員會批准使用更高劑量的 Wegovy 注射劑 | 2026 年 2 月 17 日東部時間上午 9:25（MT Newswires）-- 諾和諾德公司（NVO）週二表示，歐洲委員會已批准 Wegovy 的 7.2 毫克每週一次的維持劑量，適用於肥胖成年人。諾和諾德公司表示，此次批准是基於歐洲 | [Link](https://longbridge.com/en/news/276138110.md) |
| Rhumbline Advisers 出售了 38,557 股康西哥公司（Centene Corporation）的股票，股票代碼為$CNC | Rhumbline Advisers 已將其在 Centene Corporation (NYSE:CNC) 的持股比例降低了 3.4%，在第三季度出售了 38,557 股，剩餘持有 1,086,024 股，估值約為 3,875 萬美元。其 | [Link](https://longbridge.com/en/news/276004099.md) |
| 歐盟批准諾和諾德公司 Wegovy 藥物的更高劑量 | 歐洲委員會已批准丹麥製藥公司諾和諾德的熱門減肥藥物 Wegovy 的更高劑量，該公司在週二表示 | [Link](https://longbridge.com/en/news/276134250.md) |
| 在近期股價回調和回報表現不一的情況下，評估諾和諾德公司（CPSE:NOVO B）的估值 | 諾和諾德公司 (CPSE:NOVO B) 的回報表現不一，最近上漲了 1.7%，但在過去一個月內下跌了 17.6%。截至目前，股價下跌了 5.6%，過去一年總股東回報下降了 42.5%。分析師建議的公允價值為每股 851.04 丹麥克朗，表 | [Link](https://longbridge.com/en/news/275941659.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.